VRTX

SEC source: 0000875320-26-000044 · wk-form4_1770933367.xml · nonDerivative · entry 1

Bunnage Mark E. · CIK 0002100735 · EVP, Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,935

SEC source: 0000875320-26-000046 · wk-form4_1770933613.xml · nonDerivative · entry 1

Kewalramani Reshma · CIK 0001735944 · Director · CEO & President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 146,528

SEC source: 0000875320-26-000048 · wk-form4_1770933853.xml · nonDerivative · entry 1

McKechnie Duncan · CIK 0002062139 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,811

SEC source: 0000875320-26-000050 · wk-form4_1770933974.xml · nonDerivative · entry 1

Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,941

SEC source: 0000875320-26-000052 · wk-form4_1770934130.xml · nonDerivative · entry 1

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,902

SEC source: 0000875320-26-000054 · wk-form4_1770934225.xml · nonDerivative · entry 1

WAGNER CHARLES F JR · CIK 0001223348 · EVP, CO & FO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,280

SEC source: 0000875320-26-000010 · wk-form4_1769461800.xml · nonDerivative · entry 2

ALTSHULER DAVID · CIK 0001550395 · EVP, Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,477

F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026.

SEC source: 0000875320-26-000010 · wk-form4_1769461800.xml · nonDerivative · entry 1

ALTSHULER DAVID · CIK 0001550395 · EVP, Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,149

F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026.

SEC source: 0000875320-26-000012 · wk-form4_1769462267.xml · nonDerivative · entry 2

Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,669

F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026.

SEC source: 0000875320-26-000012 · wk-form4_1769462267.xml · nonDerivative · entry 1

Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,786

F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026.

SEC source: 0000875320-26-000014 · wk-form4_1769462440.xml · nonDerivative · entry 2

Biller Jonathan · CIK 0001744749 · EVP and Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,374

F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026.

SEC source: 0000875320-26-000014 · wk-form4_1769462440.xml · nonDerivative · entry 1

Biller Jonathan · CIK 0001744749 · EVP and Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,600

F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026.

SEC source: 0000875320-26-000016 · wk-form4_1769462535.xml · nonDerivative · entry 2

Bozic Carmen · CIK 0001790029 · EVP and CMO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,002

F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026.

SEC source: 0000875320-26-000016 · wk-form4_1769462535.xml · nonDerivative · entry 1

Bozic Carmen · CIK 0001790029 · EVP and CMO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,535

F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026.

SEC source: 0000875320-26-000018 · wk-form4_1769462741.xml · nonDerivative · entry 2

Kewalramani Reshma · CIK 0001735944 · Director · CEO & President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 154,825

F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026.

SEC source: 0000875320-26-000018 · wk-form4_1769462741.xml · nonDerivative · entry 1

Kewalramani Reshma · CIK 0001735944 · Director · CEO & President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 142,940

F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026.

SEC source: 0000875320-26-000020 · wk-form4_1769462884.xml · nonDerivative · entry 1

LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,039

F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/24/2026.

SEC source: 0000875320-26-000022 · wk-form4_1769463011.xml · nonDerivative · entry 2

McKechnie Duncan · CIK 0002062139 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,938

F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026.

SEC source: 0000875320-26-000022 · wk-form4_1769463011.xml · nonDerivative · entry 1

McKechnie Duncan · CIK 0002062139 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,858

F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026.

SEC source: 0000875320-26-000024 · wk-form4_1769463298.xml · nonDerivative · entry 2

Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,998

F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026.

SEC source: 0000875320-26-000024 · wk-form4_1769463298.xml · nonDerivative · entry 1

Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,115

F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026.

SEC source: 0000875320-26-000026 · wk-form4_1769463422.xml · nonDerivative · entry 2

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,042

F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026.

SEC source: 0000875320-26-000026 · wk-form4_1769463422.xml · nonDerivative · entry 1

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,159

F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026.

SEC source: 0000875320-26-000028 · wk-form4_1769463497.xml · nonDerivative · entry 2

WAGNER CHARLES F JR · CIK 0001223348 · EVP, CO & FO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,325

F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026.

SEC source: 0000875320-26-000028 · wk-form4_1769463497.xml · nonDerivative · entry 1

WAGNER CHARLES F JR · CIK 0001223348 · EVP, CO & FO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,165

F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026.

SEC source: 0001856587-26-000002 · wk-form4_1769461964.xml · nonDerivative · entry 2

Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,095

F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026.

SEC source: 0001856587-26-000002 · wk-form4_1769461964.xml · nonDerivative · entry 1

Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,795

F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026.

SEC source: 0000875320-26-000006 · wk-form4_1768945505.xml · derivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,564.521

Underlying: Common Stock · 107.088 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

SEC source: 0000875320-26-000008 · wk-form4_1768945675.xml · derivative · entry 1

Upadhyay Suketu · CIK 0001533149 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,718.648

Underlying: Common Stock · 80.316 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death.

SEC source: 0000875320-26-000004 · wk-form4_1767992722.xml · nonDerivative · entry 1

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 42,293

F1 · kind: Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 08/21/2025.

SEC source: 0000875320-26-000002 · wk-form4_1767906275.xml · derivative · entry 3

WAGNER CHARLES F JR · CIK 0001223348 · EVP, CO & FO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,532 shares

Expires 2029-04-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Fully vested.

SEC source: 0000875320-26-000002 · wk-form4_1767906275.xml · nonDerivative · entry 2

WAGNER CHARLES F JR · CIK 0001223348 · EVP, CO & FO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37,725

F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1, which was entered into on 5/09/2025.

SEC source: 0000875320-26-000002 · wk-form4_1767906275.xml · nonDerivative · entry 1

WAGNER CHARLES F JR · CIK 0001223348 · EVP, CO & FO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 47,257

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000875320-25-000242 · wk-form4_1764969035.xml · derivative · entry 17

LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1 shares

Expires 2026-02-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F15 · derivative.exercise_date: Fully vested.

SEC source: 0000875320-25-000242 · wk-form4_1764969035.xml · nonDerivative · entry 14

LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,027

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000875320-25-000240 · wk-form4_1764968757.xml · nonDerivative · entry 1

Biller Jonathan · CIK 0001744749 · EVP and Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,306

F1 · kind: Transaction made pursuant to Mr. Biller's company approved trading plan under Rule 10b5-1, which was entered into on 02/24/2025.

SEC source: 0000875320-25-000242 · wk-form4_1764969035.xml · derivative · entry 16

LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 63,781 shares

Expires 2027-02-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F15 · derivative.exercise_date: Fully vested.

SEC source: 0000875320-25-000242 · wk-form4_1764969035.xml · nonDerivative · entry 13

LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,026

F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 8/6/2025.

F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F14 · price: Open market sales reported on this line occurred at a weighted average price of $455.22 (range $454.88 to $455.66).

SEC source: 0000875320-25-000242 · wk-form4_1764969035.xml · nonDerivative · entry 12

LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 26,096

F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 8/6/2025.

F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F13 · price: Open market sales reported on this line occurred at a weighted average price of $453.34 (range $452.91 to $453.70).

SEC source: 0000875320-25-000242 · wk-form4_1764969035.xml · nonDerivative · entry 11

LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,456

F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 8/6/2025.

F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F12 · price: Open market sales reported on this line occurred at a weighted average price of $452.20 (range $451.73 to $452.69).

SEC source: 0000875320-25-000242 · wk-form4_1764969035.xml · nonDerivative · entry 10

LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 52,137

F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 8/6/2025.

F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F11 · price: Open market sales reported on this line occurred at a weighted average price of $451.20 (range $450.71 to $451.70).

SEC source: 0000875320-25-000242 · wk-form4_1764969035.xml · nonDerivative · entry 9

LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 57,946

F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 8/6/2025.

F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F10 · price: Open market sales reported on this line occurred at a weighted average price of $449.84 (range $449.22 to $450.18).

SEC source: 0000875320-25-000242 · wk-form4_1764969035.xml · nonDerivative · entry 8

LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 63,826

F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 8/6/2025.

F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F9 · price: Open market sales reported on this line occurred at a weighted average price of $448.78 (range $448.18 to $449.12).

SEC source: 0000875320-25-000242 · wk-form4_1764969035.xml · nonDerivative · entry 7

LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 66,146

F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 8/6/2025.

F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F8 · price: Open market sales reported on this line occurred at a weighted average price of $447.05 (range $447.00 to $447.23).

SEC source: 0000875320-25-000242 · wk-form4_1764969035.xml · nonDerivative · entry 6

LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 67,298

F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 8/6/2025.

F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F7 · price: Open market sales reported on this line occurred at a weighted average price of $445.56 (range $445.00 to $445.82).

SEC source: 0000875320-25-000242 · wk-form4_1764969035.xml · nonDerivative · entry 5

LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 75,197

F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 8/6/2025.

F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F6 · price: Open market sales reported on this line occurred at a weighted average price of $444.36 (range $444.00 to $444.94).

SEC source: 0000875320-25-000242 · wk-form4_1764969035.xml · nonDerivative · entry 4

LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 79,549

F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 8/6/2025.

F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F5 · price: Open market sales reported on this line occurred at a weighted average price of $443.21 (range $442.94 to $443.93).

SEC source: 0000875320-25-000242 · wk-form4_1764969035.xml · nonDerivative · entry 3

LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 82,018

F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 8/6/2025.

F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4 · price: Open market sales reported on this line occurred at a weighted average price of $441.26 (range $441.14 to $442.00).

SEC source: 0000875320-25-000242 · wk-form4_1764969035.xml · nonDerivative · entry 2

LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 83,338

F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 8/6/2025.

F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F3 · price: Open market sales reported on this line occurred at a weighted average price of $440.40 (range $440.04 to $441.00).

SEC source: 0000875320-25-000242 · wk-form4_1764969035.xml · nonDerivative · entry 1

LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 87,807

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.